Missak Haigentz, MD, highlights some of the significant unmet needs for patients with small cell lung cancer.
Missak Haigentz, MD
Advertisement
Missak Haigentz, MD, is the chief of thoracic medical oncology and chief of head and neck medical oncology at Rutgers Cancer Institute, professor of medicine at Rutgers Robert Wood Johnson Medical School, and clinical director of oncology integration at RWJBarnabas Health.
Articles by Missak Haigentz, MD
Missak Haigentz, MD, discusses the impact of the results from the ADRIATIC study of durvalumab as consolidation treatment after concurrent chemoradiation for the treatment of patients with limited-stage small cell lung cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
